Medical device makers should be prepared to identify and consider specific differences between patients of varying ages, races and ethnicities, and incorporate queries about subgroups into clinical trial designs and reports supporting 510(k) and premarket approval (PMA) submissions, the US Food and Drug Administration says in a guidance 1,2.
The guidance, issued June 20, also directs device sponsors– including those taking the de novo or humanitarian device exemption (HDE)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?